Trials / Completed
CompletedNCT05659537
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
A 24-week Multicenter, Open-label, Single-arm Study to Evaluate Safety in Patients With Type 2 Diabetes Mellitus in India Treated With Dulaglutide
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 212 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate safety of dulaglutide in participants with type 2 diabetes mellitus in India.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dulaglutide | Administered SC |
Timeline
- Start date
- 2022-12-29
- Primary completion
- 2024-01-16
- Completion
- 2024-01-16
- First posted
- 2022-12-21
- Last updated
- 2025-02-20
- Results posted
- 2025-02-05
Locations
7 sites across 1 country: India
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05659537. Inclusion in this directory is not an endorsement.